Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection

US11530268B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Lan Wu · Bound Brook, US
• Ling Xu · Potomac, US
• Edward SEUNG · Cambridge, US
• Ronnie Wei · Weston, US
• Gary J. Nabel · Cambridge, US
• Zhi-yong Yang · Potomac, US
• Tarik Dabdoubi · Paris, FR
• Beatrice Cameron · Paris, FR
• Cendrine Lemoine · Paris, FR
• Catherine Prades · Thiais, FR

Key dates

• Filing date: Oct 8, 2019
• Grant date: Dec 20, 2022
• Expiry date: Oct 14, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2501/998
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The disclosure provides methods of treating viral infection using trispecific binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind a CD38 polypeptide (e.g., human and/or cynomolgus monkey CD38 polypeptides), a CD28 polypeptide, and a CD3 polypeptide.